NNovo Nordisk Read More Lexicon (LXRX) Reports $21.1M Q1 Revenue Driven by Novo Nordisk Milestones2026-05-10 Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) is one of the best fast growing penny stocks to buy right now. On…
NNovo Nordisk Read More Lexicon Q1 revenue hits $21.1M, cash rises to $199.7M2026-05-07 Lexicon Pharmaceuticals (Nasdaq: LXRX) reported Q1 2026 results and pipeline updates on May…
NNovo Nordisk Read More Novo Nordisk Extends Pipeline With Semaglutide Alcohol Study And LX9851 Trial2026-05-04 Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors…
NNovo Nordisk Read More Lexicon Pharma (LXRX), Novo Nordisk (NVO) Initiate Phase 1 Study for Obesity Drug LX98512026-05-01 Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) is one of the best biotech penny stocks to buy in 2026. On March…
NNovo Nordisk Read More Lexicon earns $10M as Novo starts LX9851 Phase 12026-03-25 Lexicon Pharmaceuticals (Nasdaq: LXRX) and Novo Nordisk announced initiation of a Phase 1…
NNovo Nordisk Read More Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX98512026-03-24 Lexicon Pharmaceuticals, Inc. LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment…
NNovo Nordisk Read More Novo Nordisk (CPSE:NOVO B) Valuation Check As LX9851 Expands Its Obesity Drug Pipeline2026-03-23 Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors…